RxDoctor Payments Data

Brian Stratta, MD

Family Medicine · Hyndman, PANPI 1730140146

Payments from drug & device makers

$1,961in general payments, 2019–2025

Across 108 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$351
  • AbbVie$318
  • Exact Sciences$175
  • Indivior Inc.$152
  • Amgen$117
  • Astellas Pharma US Inc$108
  • plus $740 from 19 others

What the payments were for

  • Food & beverage$1,87696%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,961 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,086
Medicare patients
28
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$53,173
OzempicSemaglutide46$46,792
JardianceEmpagliflozin54$39,796
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,416
TrulicityDulaglutide28$26,119
MounjaroTirzepatide25$25,600
RybelsusSemaglutide23$21,730
XareltoRivaroxaban29$15,691
MyrbetriqMirabegron28$15,443
FarxigaDapagliflozin Propanediol11$6,445
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,089
Advair HfaFluticasone Propion/Salmeterol14$5,885
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,712
Atorvastatin Calcium252$2,577
Gabapentin170$2,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$351$68,52169 claims
PfizerEliquis$77$53,17372 claims
Lilly USA, LLCTrulicity, Mounjaro$26$51,71953 claims
GSKTrelegy Ellipta$33$30,41640 claims
Astellas Pharma US IncMyrbetriq$108$15,44328 claims
AbbVieSynthroid$318$1,01917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Hyndman

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →